Aims We previously identified association between the ID3 SNP rs11574 and carotid intima-media thickness in the Diabetes Heart Study, a predominantly White diabetic population. The nonsynonymous SNP rs11574 results in an amino acid substitution in the C-terminal region of ID3, attenuating the dominant negative function of ID3 as an inhibitor of basic HLH factor E12-mediated transcription. In the current investigation, we characterize the association between the functionally significant polymorphism in ID3, rs11574, with human coronary pathology. Methods and Results The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal study of subclinical cardiovascular disease, including non-Hispanic White (n = 2,588), African American (n = 2,560) and Hispanic (n = 2,130) participants with data on coronary artery calcium (CAC). The Coronary Assessment in Virginia cohort (CAVA) included 71 patients aged 30–80 years, undergoing a medically necessary cardiac catheterization and intravascular ultrasound (IVUS) at the University of Virginia. ID3 SNP rs11574 risk allele was associated with the presence of CAC in MESA Whites (P = 0.017). In addition, the risk allele was associated with greater atheroma burden and stenosis in the CAVA cohort (P = 0.003, P = 0.04 respectively). The risk allele remained predictive of atheroma burden in multivariate analysis (Model 1: covariates age, gender, and LDL, regression coefficient = 9.578, SE = 3.657, p = 0.0110; Model 2: covariates Model 1, presence of hypertension, presence of diabetes, regression coefficient = 8.389, SE = 4.788, p = 0.0163). Conclusions We present additional cohorts that demonstrate association of ID3 SNP rs11574 directly with human coronary artery pathology as measured by CAC and IVUS: one a multiethnic, relatively healthy population with low levels of diabetes and the second a predominantly White population with a higher incidence of T2DM referred for cardiac catheterization.
References
[1]
Ragosta M (2011) Techniques for phenotyping coronary artery disease in the cardiac catheterization laboratory for applications in translational research. J Cardiovasc Transl Res 4: 385–392. doi: 10.1007/s12265-011-9274-2
[2]
Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, et al. (2010) Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 55: 2399–2407. doi: 10.1016/j.jacc.2010.02.026
[3]
Calvert PA, Obaid DR, O'Sullivan M, Shapiro LM, McNab D, et al. (2011) Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 4: 894–901. doi: 10.1016/j.jcmg.2011.05.005
[4]
Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, et al. (2012) Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308: 788–795. doi: 10.1001/jama.2012.9624
[5]
Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, et al. (2012) Lymphocytes and the Adventitial Immune Response in Atherosclerosis. Circ Res 110: 889–900. doi: 10.1161/circresaha.111.263186
[6]
Lahoute C, Herbin O, Mallat Z, Tedgui A (2011) Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8: 348–358. doi: 10.1038/nrcardio.2011.62
[7]
Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12: 204–212. doi: 10.1038/ni.2001
[8]
Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. doi: 10.1038/nature01323
[9]
Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317–325. doi: 10.1038/nature10146
[10]
Lusis AJ, Mar R, Pajukanta P (2004) Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 5: 189–218. doi: 10.1146/annurev.genom.5.061903.175930
[11]
Doran AC, Lehtinen AB, Meller N, Lipinski MJ, Slayton RP, et al. (2010) Id3 is a novel atheroprotective factor containing a functionally significant single-nucleotide polymorphism associated with intima-media thickness in humans. Circ Res 106: 1303–1311. doi: 10.1161/circresaha.109.210294
[12]
Lipinski MJ, Campbell KA, Duong SQ, Welch TJ, Garmey JC, et al. (2012) Loss of Id3 increases VCAM-1 expression, macrophage accumulation, and atherogenesis in Ldlr？/？ mice. Arterioscler Thromb Vasc Biol 32: 2855–2861. doi: 10.1161/atvbaha.112.300352
[13]
Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, et al. (2013) Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol 33: 2771–2779. doi: 10.1161/atvbaha.113.302571
[14]
Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156: 871–881. doi: 10.1093/aje/kwf113
[15]
Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, et al. (2001) American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37: 1478–1492. doi: 10.1016/s0735-1097(01)01175-5
[16]
Nichaman MZ, Hamilton HB, Kagan A, Grier T, Sacks T, et al. (1975) Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: distribution of biochemical risk factors. Am J Epidemiol 102: 491–501.
[17]
Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, et al. (1986) The diet and 15-year death rate in the seven countries study. Am J Epidemiol 124: 903–915.
[18]
Chan L, Boerwinkle E (1994) Gene-Environment Interactions and Gene Therapy in Atherosclerosis. Cardiology in Review 2: 130–137. doi: 10.1097/00045415-199405000-00003
[19]
Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, et al. (2001) Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proceedings of the National Academy of Sciences of the United States of America 98: 7946–7951. doi: 10.1073/pnas.141239098
[20]
Wang Q, Rao S, Shen GQ, Li L, Moliterno DJ, et al. (2004) Premature myocardial infarction novel susceptibility locus on chromosome 1P34–36 identified by genomewide linkage analysis. American journal of human genetics 74: 262–271. doi: 10.1086/381560
[21]
Jones-Mason ME, Zhao X, Kappes D, Lasorella A, Iavarone A, et al. (2012) E protein transcription factors are required for the development of CD4(+) lineage T cells. Immunity 36: 348–361. doi: 10.1016/j.immuni.2012.02.010
[22]
Maruyama T, Li J, Vaque JP, Konkel JE, Wang W, et al. (2011) Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. Nat Immunol 12: 86–95. doi: 10.1038/ni.1965
[23]
Miyazaki M, Rivera RR, Miyazaki K, Lin YC, Agata Y, et al. (2011) The opposing roles of the transcription factor E2A and its antagonist Id3 that orchestrate and enforce the naive fate of T cells. Nat Immunol 12: 992–1001. doi: 10.1038/ni.2086
[24]
Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, et al. (2011) Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol 12: 1230–1237. doi: 10.1038/ni.2153
[25]
Yang CY, Best JA, Knell J, Yang E, Sheridan AD, et al. (2011) The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol 12: 1221–1229. doi: 10.1038/ni.2158
[26]
Guo Z, Li H, Han M, Xu T, Wu X, et al. (2011) Modeling Sjogren's syndrome with Id3 conditional knockout mice. Immunol Lett 135: 34–42. doi: 10.1016/j.imlet.2010.09.009
[27]
Li H, Dai M, Zhuang Y (2004) A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. Immunity 21: 551–560. doi: 10.1016/j.immuni.2004.08.013
[28]
Mahlios J, Zhuang Y (2011) Contribution of IL-13 to early exocrinopathy in Id3？/？ mice. Mol Immunol 49: 227–233. doi: 10.1016/j.molimm.2011.08.012
[29]
Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, et al. (2012) B-cell aortic homing and atheroprotection depend on Id3. Circ Res 110: e1–12. doi: 10.1161/circresaha.111.256438
[30]
Taylor AM, Hanchett R, Natarajan R, Hedrick CC, Forrest S, et al. (2005) The effects of leukocyte-type 12/15-lipoxygenase on Id3-mediated vascular smooth muscle cell growth. Arterioscler Thromb Vasc Biol 25: 2069–2074. doi: 10.1161/01.atv.0000178992.40088.f2
[31]
Deliri H, Meller N, Kadakkal A, Malhotra R, Brewster J, et al. (2011) Increased 12/15-lipoxygenase enhances cell growth, fibronectin deposition, and neointimal formation in response to carotid injury. Arterioscler Thromb Vasc Biol 31: 110–116. doi: 10.1161/atvbaha.110.212068
[32]
Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, et al. (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119: 1335–1349. doi: 10.1172/jci36800
[33]
Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, et al. (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48: 425–433. doi: 10.1194/jlr.m600361-jlr200
[34]
Morris-Rosenfeld S, Lipinski MJ, McNamara CA (2013) Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol doi: 10.1586/1744666x.2014.857602
